TTrialPathMatch Me to Trials
← Back to trials
RecruitingLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell LymphomaPrimary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Eligible age

18+ yrs

Accepts

All genders

Locations

11 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

Sponsor: Dren Bio

You may qualify if…

  • ✓ 1. ≥18 years of age.
  • ✓ 2. Able to understand and comply with protocol-required study procedures and voluntarily sign a written informed consent document.
  • ✓ 3. Sufficient key organ performance and coagulation.
  • ✓ 4. Female subjects of childbearing potential (postmenarcheal, has an intact uterus and at least one ovary, and is \<1 year postmenopausal) must agree to use a highly effective method of contraception from enrollment through at least 12 months after last dose of DR-01.
  • ✓ 5. Male subjects must agree to use acceptable effective method(s) of contraception.
  • ✓ Subjects with LGLL must also meet inclusion criteria 6 and 7.
  • ✓ 6. Must have discontinued at least one prior line of systemic therapy.
  • ✓ 7. Additional immunophenotypic and symptomatic criteria must be met.

You may not qualify if…

  • ✕ Disease-specific Exclusion Criteria; LGLL and ANKL:
  • ✕ 1. A reactive LGL lymphocytosis to a viral infection or LGL associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  • ✕ The following exclusion criteria apply to all subjects:
  • ✕ 2. Active systemic infection or severe localized infection requiring systemic antibiotics, antivirals or antifungals.
  • ✕ 3. Active or suspected malignant central nervous system involvement.
  • ✕ 4. Life-threatening, severe complications of malignancy (e.g., uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation).
  • ✕ 5. Active known second malignancy.
  • ✕ 6. Infection with human immunodeficiency virus (HIV) type 1 or 2 (HIV-1 or HIV-2).

Where it's recruiting

Alabama

Birmingham

California

Duarte · Irvine · Redwood City

Connecticut

New Haven

Florida

Tampa

New York

New York

Ohio

Columbus

Pennsylvania

Pittsburgh

Texas

Houston

Virginia

Charlottesville · Fairfax

Washington

Seattle · Nedlands

Source: ClinicalTrials.gov · NCT05475925 · last updated 2026-06-17

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia · TrialPath